{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:34:52Z","timestamp":1792708492576,"version":"4.5.0"},"reference-count":126,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Chronic liver diseases (CLDs), encompassing a spectrum of etiologies including metabolic dysfunction, alcohol abuse, and viral infections, represent a significant global health burden. The progression of these diseases to fibrosis, cirrhosis, and hepatocellular carcinoma is underpinned by complex immunological mechanisms in which liver-resident macrophages (LRMs) are central players. LRMs are not a monolithic population but a heterogeneous consortium of cells, primarily comprising embryonically-derived, self-renewing Kupffer cells and dynamically recruited monocyte-derived macrophages. These subsets, along with newly identified populations like lipid-associated macrophages and scar-associated macrophages, exhibit distinct origins, phenotypes, and functions that profoundly influence the trajectory of liver injury and repair. A new generation of immunomodulatory therapies is being developed to specifically target the pathways that govern LRM function. However, clinical responses to these agents have been variable, a phenomenon largely attributable to their differential effects on the diverse LRM subsets and the profound heterogeneity of the patient population. This review elucidates the complex heterogeneity of LRMs in the context of different CLDs. We dissect the mechanisms by which emerging immunomodulatory therapies\u2014including PPAR agonists, chemokine receptor antagonists, and intracellular signaling inhibitors\u2014alter the balance, phenotype, and functional output of distinct LRM populations. By integrating findings from preclinical models with outcomes from recent clinical trials, we illustrate how the specific modulation of LRM subsets correlates with therapeutic efficacy or failure. Furthermore, we discuss the critical role of LRMs in the progression to hepatocellular carcinoma and the implications for immune checkpoint inhibitor therapies. Finally, we outline the key challenges in translating these findings into clinical practice and highlight future research priorities, emphasizing the need for single-cell technologies, investigation of the gut-liver axis, and development of combination therapies. A deeper understanding of LRM biology is paramount to advancing a precision medicine approach, ultimately paving the way for more effective and personalized treatments for patients with CLD.<\/jats:p>","DOI":"10.3389\/fphar.2025.1708240","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:31:32Z","timestamp":1762756292000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Decoding the heterogeneity of liver-resident macrophages in chronic liver diseases: therapeutic responses to immunomodulatory strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Renbin","family":"Ouyang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiliang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2023.04.003","article-title":"Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study","volume":"22","author":"Anstee","year":"2024","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"101587","DOI":"10.1016\/j.jcmgh.2025.101587","article-title":"Targeting hepatic stellate cell PD-L1 alters liver inflammation and fibrosis in CCl4 liver injury mouse model","volume":"19","author":"Bai","year":"2025","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41590-023-01631-w","article-title":"Discrimination of cell-intrinsic and environment-dependent effects of natural genetic variation on kupffer cell epigenomes and transcriptomes","volume":"24","author":"Bennett","year":"2023","journal-title":"Nat. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/liv.14766","article-title":"A case series analysis of serious exacerbations of viral hepatitis and non-viral hepatic injuries in tocilizumab-treated patients","volume":"41","author":"Biehl","year":"2021","journal-title":"Liver Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.3389\/fimmu.2019.02694","article-title":"Understanding the heterogeneity of resident liver macrophages","volume":"10","author":"Bl\u00e9riot","year":"2019","journal-title":"Front. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/s41591-024-03406-8","article-title":"Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial","volume":"31","author":"Brennan","year":"2025","journal-title":"Nat. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.15403\/jgld-5901","article-title":"The mediation effects of type 2 diabetes mellitus and related biomarkers on the association of metabolic dysfunction-associated steatotic liver disease and fibrosis","volume":"34","author":"Cai","year":"2025","journal-title":"J. Gastrointestin Liver Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/jgh.16087","article-title":"Mechanism of ASK1 involvement in liver diseases and related potential therapeutic targets: a critical pathway molecule worth investigating","volume":"38","author":"Chen","year":"2023","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e14871","DOI":"10.7717\/peerj.14871","article-title":"The imbalance of liver resident macrophages polarization promotes chronic autoimmune hepatitis development in mice","volume":"11","author":"Chi","year":"2023","journal-title":"PeerJ"},{"key":"B10","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.livres.2022.06.001","article-title":"Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease","volume":"7","author":"Cho","year":"2023","journal-title":"Liver Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"116884","DOI":"10.1016\/j.bcp.2025.116884","article-title":"Macrophage-derived CCL1 targets CCR8 receptor in hepatic stellate cells to promote liver fibrosis through JAk\/STAT pathway","volume":"237","author":"Diao","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5115\/acb.21.046","article-title":"Role of macrophages in liver cirrhosis: fibrogenesis and resolution","volume":"55","author":"Elsherif","year":"2022","journal-title":"Anat. Cell Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"eadd8945","DOI":"10.1126\/sciimmunol.add8945","article-title":"Identification of a broadly fibrogenic macrophage subset induced by type 3 inflammation","volume":"8","author":"Fabre","year":"2023","journal-title":"Sci. Immunol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"5288","DOI":"10.4049\/jimmunol.178.8.5288","article-title":"Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis","volume":"178","author":"Fallowfield","year":"2007","journal-title":"J. Immunol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"107809","DOI":"10.1016\/j.intimp.2021.107809","article-title":"Rosiglitazone ameliorated airway inflammation induced by cigarette smoke via inhibiting the M1 macrophage polarization by activating PPAR\u03b3 and RXR\u03b1","volume":"97","author":"Feng","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"994480","DOI":"10.3389\/fimmu.2022.994480","article-title":"Distinct spatial distribution and roles of kupffer cells and monocyte-derived macrophages in mouse acute liver injury","volume":"13","author":"Flores Molina","year":"2022","journal-title":"Front. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0335","DOI":"10.1097\/HC9.0000000000000335","article-title":"Phase 2, open-label, rollover study of cenicriviroc for liver fibrosis associated with metabolic dysfunction-associated steatohepatitis","volume":"8","author":"Francque","year":"2024","journal-title":"Hepatol. Commun."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e2405746121","DOI":"10.1073\/pnas.2405746121","article-title":"Lipid-associated macrophages\u2019 promotion of fibrosis resolution during MASH regression requires TREM2","volume":"121","author":"Ganguly","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"B20","doi-asserted-by":"publisher","first-page":"968879","DOI":"10.3389\/fimmu.2022.968879","article-title":"The versatility of macrophage heterogeneity in liver fibrosis","volume":"13","author":"Gao","year":"2022","journal-title":"Front. Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1016\/j.apsb.2025.02.018","article-title":"Design, molecular characterization and therapeutic investigation of a novel CCR8 peptide antagonist that attenuates acute liver injury by inhibiting infiltration and activation of macrophages","volume":"15","author":"Geervliet","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"B22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-pharmtox-020524-012013","article-title":"Immunoregulation of liver fibrosis: new opportunities for antifibrotic therapy","volume":"65","author":"Gilgenkrantz","year":"2025","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-025-02124-y","article-title":"Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets","volume":"10","author":"Guan","year":"2025","journal-title":"Signal Transduct. Target Ther."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e000003","DOI":"10.1136\/egastro-2023-000003","article-title":"Spatial dimension of macrophage heterogeneity in liver diseases","volume":"1","author":"Guillot","year":"2023","journal-title":"eGastroenterology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/j.immuni.2024.08.016","article-title":"Notch signaling regulates macrophage-mediated inflammation in metabolic dysfunction-associated steatotic liver disease","volume":"57","author":"Guo","year":"","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1336493","DOI":"10.3389\/fimmu.2024.1336493","article-title":"Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications","volume":"15","author":"Guo","year":"","journal-title":"Front. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e180943","DOI":"10.1172\/jci.insight.180943","article-title":"Circulating metabolite signatures indicate differential gut-liver crosstalk in lean and Obese MASLD","volume":"10","author":"Haag","year":"2025","journal-title":"JCI Insight"},{"key":"B28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4062\/biomolther.2023.203","article-title":"Selonsertib, an ASK1 inhibitor, ameliorates ovalbumin-induced allergic asthma during challenge and sensitization periods","volume":"32","author":"Han","year":"2024","journal-title":"Biomol. Ther. Seoul."},{"key":"B29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials","volume":"73","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jhep.2022.06.004","article-title":"Soluble TREM2 levels reflect the recruitment and expansion of TREM2+ macrophages that localize to fibrotic areas and limit NASH","volume":"77","author":"Hendrikx","year":"2022","journal-title":"J. Hepatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"19805","DOI":"10.1038\/s41598-022-23858-7","article-title":"Uptake of Plasmodium chabaudi hemozoin drives kupffer cell death and fuels superinfections","volume":"12","author":"Hirako","year":"2022","journal-title":"Sci. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"113482","DOI":"10.1016\/j.ejmech.2021.113482","article-title":"Design, synthesis and biological evaluation of 1H-indazole derivatives as novel ASK1 inhibitors","volume":"220","author":"Hou","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"802","DOI":"10.14218\/JCTH.2024.00123","article-title":"Pipeline of new drug treatment for non-alcoholic fatty liver disease\/metabolic dysfunction-associated steatotic liver disease","volume":"12","author":"Hu","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e70735","DOI":"10.1096\/fj.202500718R","article-title":"Fibrogenic gene signature as early prediction for the efficacy of pharmacological interventions for MASH-associated fibrosis","volume":"39","author":"Inia","year":"2025","journal-title":"FASEB J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/hep4.1723","article-title":"Deuterium-stabilized (R)-Pioglitazone (PXL065) is responsible for pioglitazone efficacy in NASH yet exhibits little to no PPAR\u03b3 activity","volume":"5","author":"Jacques","year":"2021","journal-title":"Hepatol. Commun."},{"key":"B36","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1039\/d4bm00874j","article-title":"Amplified response of drug-induced liver fibrosis via immune cell co-culture in a 3D in vitro hepatic fibrosis model","volume":"12","author":"Jung","year":"2024","journal-title":"Biomater. Sci."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.3390\/biom13081264","article-title":"Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease","volume":"13","author":"Kamata","year":"2023","journal-title":"Biomolecules"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e165369","DOI":"10.1172\/jci.insight.165369","article-title":"Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis","volume":"8","author":"Kang","year":"2023","journal-title":"JCI Insight"},{"key":"B39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41575-018-0082-x","article-title":"The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"16","author":"Kazankov","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1129831","DOI":"10.3389\/fmolb.2023.1129831","article-title":"The contradictory roles of macrophages in non-alcoholic fatty liver disease and primary liver cancer-challenges and opportunities","volume":"10","author":"Kohlhepp","year":"2023","journal-title":"Front. Mol. Biosci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/ng.2901","article-title":"Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease","volume":"46","author":"Kozlitina","year":"2014","journal-title":"Nat. Genet."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1111\/liv.15845","article-title":"Impact of PNPLA3 and TM6SF2 polymorphisms on the prognosis of patients with MASLD and type 2 diabetes mellitus","volume":"44","author":"Lavrado","year":"2024","journal-title":"Liver Int."},{"key":"B43","doi-asserted-by":"publisher","first-page":"166","DOI":"10.5483\/BMBRep.2022.55.4.022","article-title":"Roles of heterogenous hepatic macrophages in the progression of liver diseases","volume":"55","author":"Lee","year":"2022","journal-title":"BMB Rep."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.04.025","article-title":"Safety and efficacy of elafibranor in primary sclerosing cholangitis: the ELMWOOD phase II randomized-controlled trial","author":"Levy","year":"2025","journal-title":"J. Hepatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1021\/acsbiomaterials.0c01610","article-title":"Tissue-specific hydrogels ameliorate hepatic ischemia\/Reperfusion injury in rats by regulating macrophage polarization via TLR4\/NF-\u03baB signaling","volume":"7","author":"Li","year":"","journal-title":"ACS Biomater. Sci. Eng."},{"key":"B46","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41420-021-00584-z","article-title":"Mesenchymal stem cells attenuate liver fibrosis by targeting Ly6Chi\/lo macrophages through activating the cytokine-paracrine and apoptotic pathways","volume":"7","author":"Li","year":"","journal-title":"Cell Death Discov."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1455383","DOI":"10.3389\/fimmu.2024.1455383","article-title":"Integrated single-cell and bulk RNA sequencing reveals immune-related SPP1+ macrophages as a potential strategy for predicting the prognosis and treatment of liver fibrosis and hepatocellular carcinoma","volume":"15","author":"Li","year":"","journal-title":"Front. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1382256","DOI":"10.3389\/fphar.2024.1382256","article-title":"Tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for hepatocellular carcinoma: recent research progress","volume":"15","author":"Li","year":"","journal-title":"Front. Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3390\/cells12030341","article-title":"TREM2 regulates the removal of apoptotic cells and inflammatory processes during the progression of NAFLD","volume":"12","author":"Liebold","year":"2023","journal-title":"Cells"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e16186","DOI":"10.1111\/liv.16186","article-title":"Targeting PNPLA3 to treat MASH and MASH related fibrosis and cirrhosis","volume":"45","author":"Lind\u00e9n","year":"2025","journal-title":"Liver Int."},{"key":"B51","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1267\/ahc.24-00046","article-title":"Effect of hepatic lipid overload on accelerated hepatocyte proliferation promoted by HGF expression via the SphK1\/S1PR2 pathway in MCD-Diet mouse partial hepatectomy","volume":"57","author":"Lkham-Erdene","year":"2024","journal-title":"Acta Histochem Cytochem"},{"key":"B52","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/hep.31622","article-title":"Combination therapies including cilofexor and firsocostat for bridging fibrosis and cirrhosis attributable to NASH","volume":"73","author":"Loomba","year":"2021","journal-title":"Hepatology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"892114","DOI":"10.3389\/fimmu.2022.892114","article-title":"Susceptibility to infections during acute liver injury depends on transient disruption of liver macrophage niche","volume":"13","author":"Lopes","year":"2022","journal-title":"Front. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"44612","DOI":"10.1038\/srep44612","article-title":"Effect of modulation of PPAR-\u03b3 activity on kupffer cells M1\/M2 polarization in the development of non-alcoholic fatty liver disease","volume":"7","author":"Luo","year":"2017","journal-title":"Sci. Rep."},{"key":"B55","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2017.05.022","article-title":"Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice","volume":"67","author":"Ma","year":"2017","journal-title":"J. Hepatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3390\/nu15092068","article-title":"Innate immune system in the pathogenesis of non-alcoholic fatty liver disease","volume":"15","author":"Ma","year":"2023","journal-title":"Nutrients"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1494250","DOI":"10.3389\/fimmu.2024.1494250","article-title":"The role of macrophages in liver fibrosis: composition, heterogeneity, and therapeutic strategies","volume":"15","author":"Ma","year":"2024","journal-title":"Front. Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e2350847","DOI":"10.1002\/eji.202350847","article-title":"Cenicriviroc, a CCR2\/CCR5 antagonist, promotes the generation of type 1 regulatory T cells","volume":"54","author":"Madan","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/ar.25562","article-title":"Lipopolysaccharide, arbiter of the gut-liver axis, modulates hepatic cell pathophysiology in alcoholism","volume":"308","author":"Mak","year":"2025","journal-title":"Anat. Rec. Hob."},{"key":"B60","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.3390\/biomedicines11102659","article-title":"Dynamics of liver macrophage subsets in a novel mouse model of non-alcoholic steatohepatitis using C57BL\/6 mice","volume":"11","author":"Makiuchi","year":"2023","journal-title":"Biomedicines"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e43635","DOI":"10.7759\/cureus.43635","article-title":"Vitamin E and pioglitazone: a comprehensive systematic review of their efficacy in non-alcoholic fatty liver disease","volume":"15","author":"Mazhar","year":"2023","journal-title":"Cureus"},{"key":"B62","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41586-024-07372-6","article-title":"Periportal macrophages protect against commensal-driven liver inflammation","volume":"629","author":"Miyamoto","year":"2024","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","first-page":"652172","DOI":"10.3389\/fimmu.2021.652172","article-title":"Lessons from immune checkpoint inhibitor trials in hepatocellular carcinoma","volume":"12","author":"Mohr","year":"2021","journal-title":"Front. Immunol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1038\/s41591-019-0599-8","article-title":"Safety profile of autologous macrophage therapy for liver cirrhosis","volume":"25","author":"Moroni","year":"2019","journal-title":"Nat. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1293\/tox.2021-0018","article-title":"LPS-TLR4\/MD-2-TNF-\u03b1 signaling mediates alcohol-induced liver fibrosis in rats","volume":"35","author":"Mou","year":"2022","journal-title":"J. Toxicol. Pathol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jhep.2024.07.007","article-title":"Infection history imprints prolonged changes to the epigenome, transcriptome and function of kupffer cells","volume":"81","author":"Musrati","year":"2024","journal-title":"J. Hepatol."},{"key":"B67","first-page":"371","article-title":"Update on clinical trials for nonalcoholic steatohepatitis","volume":"19","author":"Nathani","year":"2023","journal-title":"Gastroenterol. Hepatol. (N Y)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/TP.0000000000001552","article-title":"Bruton tyrosine kinase inhibition attenuates liver damage in a mouse warm ischemia and reperfusion model","volume":"101","author":"Palumbo","year":"2017","journal-title":"Transplantation"},{"key":"B69","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jcmgh.2023.08.013","article-title":"Hepatocyte FoxO1 deficiency protects from liver fibrosis via reducing inflammation and TGF-\u03b21-mediated HSC activation","volume":"17","author":"Pan","year":"2024","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s12276-025-01408-1","article-title":"A1AT dysregulation of metabolically stressed hepatocytes by kupffer cells drives MASH and fibrosis","volume":"57","author":"Park","year":"2025","journal-title":"Exp. Mol. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/hep.31790","article-title":"Macrophage heterogeneity in NASH: more than just nomenclature","volume":"74","author":"Parthasarathy","year":"2021","journal-title":"Hepatology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/HEP.0000000000000801","article-title":"ASK1\/p38 axis inhibition blocks the release of mitochondrial \u201cdanger signals\u201d from hepatocytes and suppresses progression to cirrhosis and liver cancer","volume":"80","author":"Peng","year":"2024","journal-title":"Hepatology"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/stem.3449","article-title":"Human induced pluripotent stem cell-derived macrophages ameliorate liver fibrosis","volume":"39","author":"Pouyanfard","year":"2021","journal-title":"Stem Cells"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","first-page":"119631","DOI":"10.1016\/j.jep.2025.119631","article-title":"Fermented cordyceps powder alleviates silica-induced inflammation and fibrosis by inhibiting M1 macrophage polarization via the HMGB1-TLR4-NF-\u03baB pathway","volume":"345","author":"Pu","year":"2025","journal-title":"J. Ethnopharmacol."},{"key":"B76","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.1111\/bph.15182","article-title":"Inhibition of Bruton\u2019s TK regulates macrophage NF-\u03baB and NLRP3 inflammasome activation in metabolic inflammation","volume":"177","author":"Purvis","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3390\/biom14060700","article-title":"Macrophage perspectives in liver diseases: programmed death, related biomarkers, and targeted therapy","volume":"14","author":"Qian","year":"2024","journal-title":"Biomolecules"},{"key":"B78","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-019-1631-3","article-title":"Resolving the fibrotic niche of human liver cirrhosis at single-cell level","volume":"575","author":"Ramachandran","year":"2019","journal-title":"Nature"},{"key":"B79","doi-asserted-by":"publisher","first-page":"e0602","DOI":"10.1097\/HC9.0000000000000602","article-title":"Key role of macrophages in the progression of hepatic fibrosis","volume":"9","author":"Ran","year":"2025","journal-title":"Hepatol. Commun."},{"key":"B80","doi-asserted-by":"publisher","first-page":"111598","DOI":"10.1016\/j.intimp.2024.111598","article-title":"Wuling capsule modulates macrophage polarization by inhibiting the TLR4-NF-\u03baB signaling pathway to relieve liver fibrosis","volume":"129","author":"Ren","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/vim.2022.0180","article-title":"Clinical significance of evaluation of monocytic receptors in patients with hepatitis C virus infection","volume":"36","author":"Riad","year":"2023","journal-title":"Viral Immunol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jhep.2020.04.034","article-title":"STELLAR 3 and STELLAR 4: lessons from the fall of icarus","volume":"73","author":"Rinella","year":"2020","journal-title":"J. Hepatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"111036","DOI":"10.1016\/j.intimp.2023.111036","article-title":"Monocyte-derived macrophages contribute to the deterioration of immunological liver injury in mice","volume":"124","author":"Ruiqi","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"2023.02.16.23285924","DOI":"10.1101\/2023.02.16.23285924","article-title":"Patients with fibrosis from non-alcoholic steatohepatitis have heterogeneous intrahepatic macrophages and therapeutic targets","volume":"2023","author":"Saldarriaga","year":"2023","journal-title":"medRxiv."},{"key":"B85","doi-asserted-by":"publisher","first-page":"100958","DOI":"10.1016\/j.jhepr.2023.100958","article-title":"Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis","volume":"6","author":"Saldarriaga","year":"2024","journal-title":"JHEP Rep."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e175241","DOI":"10.1172\/JCI175241","article-title":"Virus-associated inflammation imprints an inflammatory profile on monocyte-derived macrophages in the human liver","volume":"135","author":"Sanchez Vasquez","year":"2025","journal-title":"J. Clin. Invest"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1232070","DOI":"10.3389\/fimmu.2024.1232070","article-title":"Diverse potential of secretome from natural killer cells and monocyte-derived macrophages in activating stellate cells","volume":"15","author":"Sauer","year":"2024","journal-title":"Front. Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"16452","DOI":"10.3390\/ijms242216452","article-title":"Sex drives functional changes in the progression and regression of liver fibrosis","volume":"24","author":"Sayaf","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"11636","DOI":"10.3390\/ijms231911636","article-title":"Evogliptin directly inhibits inflammatory and fibrotic signaling in isolated liver cells","volume":"23","author":"Seo","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"e0290532","DOI":"10.1371\/journal.pone.0290532","article-title":"Lobeglitazone inhibits LPS-Induced NLRP3 inflammasome activation and inflammation in the liver","volume":"18","author":"Seo","year":"2023","journal-title":"PLoS One"},{"key":"B91","doi-asserted-by":"publisher","first-page":"138510","DOI":"10.1016\/j.ijbiomac.2024.138510","article-title":"PPAR\u03b1 agonist ameliorates cholestatic liver injury by regulating hepatic macrophage homeostasis","volume":"287","author":"Shi","year":"","journal-title":"Int. J. Biol. Macromol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1604837","DOI":"10.3389\/fimmu.2025.1604837","article-title":"TREM2 in MASH: integrating lipid metabolism and immune response","volume":"16","author":"Shi","year":"","journal-title":"Front. Immunol."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000001160","article-title":"Reprogramming macrophages to treat liver diseases","author":"Sim\u00f3n-Codina","year":"2024","journal-title":"Hepatology"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.ajpath.2020.08.014","article-title":"Kupffer cells: inflammation pathways and cell-cell interactions in alcohol-associated liver disease","volume":"190","author":"Slevin","year":"2020","journal-title":"Am. J. Pathol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"103233","DOI":"10.1016\/j.isci.2021.103233","article-title":"Single-cell RNA transcriptome landscape of hepatocytes and non-parenchymal cells in healthy and NAFLD mouse liver","volume":"24","author":"Su","year":"2021","journal-title":"iScience"},{"key":"B96","doi-asserted-by":"publisher","first-page":"106170","DOI":"10.1016\/j.cct.2020.106170","article-title":"A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study","volume":"98","author":"Sven","year":"2020","journal-title":"Contemp. Clin. Trials"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jhep.2017.02.026","article-title":"Targeting hepatic macrophages to treat liver diseases","volume":"66","author":"Tacke","year":"2017","journal-title":"J. Hepatol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"13251","DOI":"10.3390\/ijms232113251","article-title":"Roles of macrophages in advanced liver fibrosis, identified using a newly established mouse model of diet-induced non-alcoholic steatohepatitis","volume":"23","author":"Tada","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"15256","DOI":"10.3390\/ijms242015256","article-title":"Dysbiotic gut microbiota-derived metabolites and their role in non-communicable diseases","volume":"24","author":"Tan","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B100","doi-asserted-by":"publisher","first-page":"154410","DOI":"10.1016\/j.prp.2023.154410","article-title":"Role of targeting TLR4 signaling axis in liver-related diseases","volume":"244","author":"Tang","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"B101","doi-asserted-by":"publisher","first-page":"110031","DOI":"10.1016\/j.jnutbio.2025.110031","article-title":"Theaflavin-3,3\u2019-digallate prevents alcoholic liver injury by suppressing hepatic TLR4\/NF-\u03baB signaling and modulating the gut-liver axis in mice","volume":"145","author":"Tang","year":"2025","journal-title":"J. Nutr. Biochem."},{"key":"B102","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1007\/s11010-025-05330-y","article-title":"Updated insights on ASK1 signaling: mechanisms, regulation, and therapeutic potential in diseases","volume":"480","author":"Thakur","year":"2025","journal-title":"Mol. Cell Biochem."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.3389\/fimmu.2019.02852","article-title":"Therapeutic targeting of hepatic macrophages for the treatment of liver diseases","volume":"10","author":"van der Heide","year":"2019","journal-title":"Front. Immunol."},{"key":"B104","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41423-020-00579-3","article-title":"Immunological mechanisms and therapeutic targets of fatty liver diseases","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1098056","DOI":"10.3389\/fimmu.2023.1098056","article-title":"Characteristic gene expression in the liver monocyte-macrophage-DC system is associated with the progression of fibrosis in NASH","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12964-024-01473-5","article-title":"Mutual regulation of PD-L1 immunosuppression between tumor-associated macrophages and tumor cells: a critical role for exosomes","volume":"22","author":"Wang","year":"","journal-title":"Cell Commun. Signal"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1414594","DOI":"10.3389\/fimmu.2024.1414594","article-title":"Hepatic macrophage niche: a bridge between HBV-mediated metabolic changes with intrahepatic inflammation","volume":"15","author":"Wang","year":"","journal-title":"Front. Immunol."},{"key":"B108","doi-asserted-by":"publisher","first-page":"101420","DOI":"10.1016\/j.xcrm.2024.101420","article-title":"PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer","volume":"5","author":"Wang","year":"","journal-title":"Cell Rep. Med."},{"key":"B109","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41423-020-00558-8","article-title":"Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities","volume":"18","author":"Wen","year":"2021","journal-title":"Cell Mol. Immunol."},{"key":"B110","doi-asserted-by":"publisher","first-page":"1569915","DOI":"10.3389\/fimmu.2025.1569915","article-title":"The microenvironment in the development of MASLD-MASH-HCC and associated therapeutic in MASH-HCC","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Immunol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"627927","DOI":"10.3389\/fmed.2021.627927","article-title":"Activated hepatic stellate cells induce infiltration and formation of CD163+ macrophages via CCL2\/CCR2 pathway","volume":"8","author":"Xi","year":"2021","journal-title":"Front. Med. (Lausanne)"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1423936","DOI":"10.3389\/fcell.2024.1423936","article-title":"Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy","volume":"12","author":"Xia","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"B113","doi-asserted-by":"publisher","first-page":"109839","DOI":"10.1016\/j.cbi.2022.109839","article-title":"TJ-M2010-5, A self-developed MyD88 inhibitor, attenuates liver fibrosis by inhibiting the NF-\u03baB pathway","volume":"354","author":"Xie","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"B114","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.molcel.2019.07.028","article-title":"Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis","volume":"75","author":"Xiong","year":"2019","journal-title":"Mol. Cell"},{"key":"B115","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/s42003-025-08387-z","article-title":"Identification of conserved and tissue-restricted transcriptional profiles for lipid associated macrophages","volume":"8","author":"Xu","year":"2025","journal-title":"Commun. Biol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13045-017-0430-2","article-title":"Tumor-associated macrophages: from basic research to clinical application","volume":"10","author":"Yang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"e17116","DOI":"10.1016\/j.heliyon.2023.e17116","article-title":"Exploring the potential of treating chronic liver disease targeting the PI3K\/Akt pathway and polarization mechanism of macrophages","volume":"9","author":"Yang","year":"2023","journal-title":"Heliyon"},{"key":"B118","doi-asserted-by":"publisher","first-page":"123881","DOI":"10.1016\/j.lfs.2025.123881","article-title":"PPAR\u03b3 agonist alleviates sepsis-related liver injury by modulating M1\/M2 macrophage polarization via the PPAR\u03b3\/I\u03baB\u03b1\/NF-\u03baB pathway","volume":"379","author":"Yang","year":"2025","journal-title":"Life Sci."},{"key":"B119","doi-asserted-by":"publisher","first-page":"115755","DOI":"10.1016\/j.taap.2021.115755","article-title":"Anemoside A3 activates TLR4-dependent M1-phenotype macrophage polarization to represses breast tumor growth and angiogenesis","volume":"432","author":"Yin","year":"2021","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"111960","DOI":"10.1016\/j.diabres.2024.111960","article-title":"Type 2 diabetes and the minor allele of PNPLA3 consistently identify high-risk metabolic dysfunction associated steatotic liver disease","volume":"219","author":"Younossi","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B121","doi-asserted-by":"publisher","first-page":"100065","DOI":"10.1016\/j.molpha.2025.100065","article-title":"The peroxisome proliferator-activated receptor \u03b1\/\u03b2\/\u03b3 agonist NCPC-626 from microbial metabolites alleviates metabolic dysfunction-associated steatohepatitis in mice","volume":"107","author":"Yu","year":"2025","journal-title":"Mol. Pharmacol."},{"key":"B122","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41419-025-07568-2","article-title":"CXCL13 suppresses liver regeneration through the negative regulation of HGF signaling","volume":"16","author":"Zhao","year":"2025","journal-title":"Cell Death Dis."},{"key":"B123","doi-asserted-by":"publisher","first-page":"2210959","DOI":"10.1080\/2162402X.2023.2210959","article-title":"M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance","volume":"12","author":"Zheng","year":"2023","journal-title":"Oncoimmunology"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1070208","DOI":"10.3389\/fcell.2022.1070208","article-title":"Crosstalk between liver macrophages and gut microbiota: an important component of inflammation-associated liver diseases","volume":"10","author":"Zhou","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"B125","doi-asserted-by":"publisher","first-page":"00196","DOI":"10.1016\/j.tem.2025.09.004","article-title":"Mechanisms and therapeutic insights into MASH-associated fibrosis","author":"Zhu","year":"2025","journal-title":"Trends Endocrinol. Metab."},{"key":"B126","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1136\/gutjnl-2019-318419","article-title":"Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade","volume":"68","author":"Zhu","year":"2019","journal-title":"Gut"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1708240\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:31:35Z","timestamp":1762756295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1708240\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":126,"alternative-id":["10.3389\/fphar.2025.1708240"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1708240","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"1708240"}}